The DOI matches its Crossref record.
Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease
Open accessAbstract
Background —In arterial hypertension, left ventricular hypertrophy (LVH) includes myocyte hypertrophy and fibrosis, which leads to LV diastolic dysfunction and, finally, heart failure. In spontaneously hypertensive rats, myocardial fibrosis was regressed and LV diastolic function was improved by treatment with the angiotensin-converting enzyme inhibitor lisinopril. Whether this holds true for patients with hypertensive heart disease was addressed in this prospective, randomized, double-blind trial. Methods and Results —A total of 35 patients with primary hypertension, LVH, and LV diastolic dysfunction were treated with either lisinopril (n=18) or hydrochlorothiazide (HCTZ; n=17). At baseline and after 6 months, LV catheterization with endomyocardial biopsy, Doppler echocardiography with measurements of LV peak flow velocities during early filling and atrial contraction and isovolumic relaxation time, and 24-hour blood pressure monitoring were performed. Myocardial fibrosis was measured by LV collagen volume fraction and myocardial hydroxyproline concentration. With lisinopril, collagen volume fraction decreased from 6.9±0.6% to 6.3±0.6% ( P <0.05 versus HCTZ) and myocardial hydroxyproline concentration from 9.9±0.3 to 8.3±0.4 μg/mg of LV dry weight ( P <0.00001 versus HCTZ); this was associated with an increase in the early filling and atrial contraction LV peak flow velocity ratio from 0.72±0.04 to 0.91±0.06 ( P <0.05 versus HCTZ) and a decrease in isovolumic relaxation time from 123±9 to 81±5 ms ( P <0.00002 versus HCTZ). Normalized blood pressure did not significantly change in either group. No LVH regression occurred in lisinopril-treated patients, whereas with HCTZ, myocyte diameter was reduced from 22.1±0.6 to 20.7±0.7 μm ( P <0.01 versus lisinopril). Conclusions —In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Dweck, M. R., Boon, N. A., & Newby, D. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.093 · Cited by 692
Cardiomyocyte stiffness in diastolic heart failure
Borbély, A., van der Velden, J., Papp, Z., Bronzwaer, J. G. F., Edes, I., Stienen, G. J. M., & Paulus, W. J. (2005) · Circulation · doi:10.1161/01.cir.0000155257.33485.6d · Cited by 536
Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy
Schlaich, M. P., Kaye, D. M., Lambert, E., Sommerville, M., Socratous, F., & Esler, M. D. (2003) · Circulation · doi:10.1161/01.cir.0000081775.72651.b6 · Cited by 459
Lim, D.-S., Lutucuta, S., Bachireddy, P., Youker, K., Evans, A., Entman, M., Roberts, R., & Marian, A. J. (2001) · Circulation · doi:10.1161/01.cir.103.6.789 · Cited by 386
Metadata
- Authors
- Brilla, C. G., Funck, R. C., & Rupp, H.
- Venue
- Circulation
- Published
- 2000-09-19
- Volume
- 102
- Issue
- 12
- Pages
- 1388-1393
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2104357833
- Cited by
- 649
- References
- 0
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease. https://app.cochat.ai/papers/10.1161/01.cir.102.12.1388
- The paper
- Brilla, C. G., Funck, R. C., & Rupp, H. (2000). Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease. Circulation. https://doi.org/10.1161/01.cir.102.12.1388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.